Minerva Neurosciences, Inc. — Q1 2017 Form 10-Q
Business context and reporting period
Clinical-stage biopharmaceutical company developing CNS therapies; it had no approved products and generated no product or licensing revenue. This unaudited report covers the three months ended March 31, 2017, compared with the same 2016 period.
- Programs: MIN-101 for schizophrenia; MIN-202, co-developed with Janssen, for insomnia and major depressive disorder (MDD); MIN-117 for MDD; and preclinical MIN-301 for Parkinson’s disease.
Financial performance and liquidity
| Metric | Q1 2017 | Q1 2016 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $7.6 million | $5.4 million |
| General and administrative expense | $2.9 million | $2.4 million |
| Total expenses / operating loss | $10.5 million / $(10.5) million | $7.8 million / $(7.8) million |
| Net loss | $(10.6) million; $(0.30) per share | $(8.0) million; $(0.29) per share |
| Operating cash flow | $(6.0) million | $(6.0) million |
| Cash, cash equivalents and marketable securities | $85.4 million at March 31 | $83.0 million cash and cash equivalents at December 31, 2016; no marketable securities reported then |
There is no meaningful operating margin because the company had no revenue. R&D expense rose $2.2 million, mainly from MIN-202 Phase II preparation and higher stock compensation, partly offset by completion of MIN-101 and MIN-117 trials. G&A rose about $0.5 million on legal and professional fees, personnel costs and stock compensation.
- Cash and cash equivalents were $68.9 million; marketable securities were $16.5 million, consisting of short-term corporate bonds with about four months’ weighted-average remaining maturity. The quarter’s $16.5 million investing outflow primarily reflected purchases of these securities.
- Cash declined $14.1 million during the quarter. Financing provided $8.4 million, including $9.4 million from warrant exercises, partly offset by $1.2 million of loan repayments.
- Notes payable totaled $7.6 million in carrying value, including $5.0 million current and $2.6 million noncurrent; principal outstanding was $7.2 million. The fixed-rate loan bears 7.05% interest, matures August 2018, and is secured by substantially all assets other than intellectual property. The company reported covenant compliance.
- Accumulated deficit was $143.5 million. Management stated existing cash, cash equivalents and marketable securities should cover commitments for at least 12 months after issuance of the statements, but additional capital will be needed for later-stage development.
Material changes, outlook and risks
- Net loss increased $2.6 million year over year; weighted-average shares rose to 35.4 million from 27.2 million. During Q1, warrant and option exercises added approximately 1.7 million shares.
- After an FDA end-of-Phase II meeting for MIN-101, the company expected to begin Phase III development in the U.S. and Europe in the second half of 2017. MIN-117 U.S. trials were expected to begin in late 2017. These are plans, not assurances.
- For MIN-202, supportive studies were underway ahead of further trials in insomnia and MDD. The company expected to pay Janssen up to an additional $15.2 million as eligible Phase II costs are incurred; Q1 included $3.2 million of collaboration expense and accrued collaborative expenses were $3.1 million.
- Management expects continued operating losses and negative operating cash flow. Funding needs depend on clinical-trial timing, results and costs; unavailable or unacceptable financing could force development to be scaled back or discontinued. Equity financing could dilute shareholders; debt or partnering could impose restrictions or require relinquishing rights.
- Key development risks include clinical failure, regulatory delays, trial enrollment and execution, manufacturing and third-party reliance, and safety. MIN-101 studies monitored QTcF prolongation; two patients in the Phase IIb core trial were discontinued for QTcF criteria, both at the higher dose. The filing also identifies potential cardiac and other adverse events for candidates.
- No material litigation was identified, and the company reported no material changes in contractual obligations. Disclosure controls were judged effective at a reasonable assurance level; no material quarter-specific change in internal control was reported.
Investor verification points
- Confirm the timing, design and FDA/European regulatory feedback for planned MIN-101 Phase III trials and the expected MIN-117 U.S. trial start.
- Track cash burn, trial commitments and whether the stated 12-month liquidity runway remains adequate as development spending changes.
- Verify Janssen’s continued participation, MIN-202 development spending and any decisions or milestones affecting the collaboration.
- Review emerging safety data, particularly QTcF monitoring for MIN-101, and whether later-stage trials reproduce earlier efficacy findings.
- Assess potential dilution from future financing and equity awards, alongside scheduled debt repayments and the loan’s asset-security and covenant terms.